EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus–Associated Cryptococcal Meningitis to High-Income Settings?

Thomas S Harrison, David S Lawrence, Henry C Mwandumba, David R Boulware, Mina C Hosseinipour, Olivier Lortholary, Graeme Meintjes, Mosepele Mosepele, Joseph N Jarvis iD

Clinical Infectious Diseases · 04.03.2023 · 76 (5) · 944-949

DOI: 10.1093/cid/ciac792 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Clinical Infectious Diseases, online erschienen am 27.09.2022. Verfasst von Thomas S Harrison und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Infection and Immunity, St George's University London, London, United Kingdom. Hauptthemen laut MEDLINE: HIV Infections, Meningitis, Cryptococcal. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, NINDS NIH HHS, National Institute for Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The AmBisome Therapy Induction Optimization (AMBITION-cm) trial, conducted in eastern and southern Africa, showed that a single, high dose (10 mg/kg) of liposomal amphotericin B, given with an oral backbone of fluconazole and flucytosine, was noninferior to the World Health Organization (WHO)–recommended regimen of 7 days of amphotericin B deoxycholate plus flucytosine for treatment of human immunodeficiency virus (HIV)–associated cryptococcal meningitis and has been incorporated into WHO treatment guidelines. We believe that the trial also has important implications for the treatment of HIV-associated cryptococcal meningitis in high-income settings. We advance the arguments, supported by evidence where available, that the AMBITION-cm trial regimen is likely to be as fungicidal as the currently recommended 14-day liposomal amphotericin–based treatments, better tolerated with fewer adverse effects, and confer significant economic and practical benefits and, therefore, should be included as a treatment option in guidance for HIV-associated cryptococcal treatment in high-income settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsMeningitis, CryptococcalHumansAntifungal AgentsDrug Therapy, CombinationFluconazoleFlucytosineHIVAmphotericin B

Stichwörter der Autor:innen

HIVamphotericin Bcryptococcal meningitisfluconazoleflucytosine

Substanzen

Antifungal AgentsFluconazoleFlucytosineliposomal amphotericin BAmphotericin B

Autor:innen und Institutionen

  • Institute of Infection and Immunity, St George's University London, London, United Kingdom.
  • Clinical Academic Group in Infection and Immunity, St George's University Hospitals NHS Foundation Trust, London, United Kingdom.
  • Medical Research Council Centre for Medical Mycology, University of Exeter, Exeter, United Kingdom.
  • Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
  • Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
  • Clinical Sciences Department, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

ORCID-Profile: Joseph N Jarvis

Förderung

  • Medical Research Council
  • NINDS NIH HHS
  • National Institute for Health Research

Zitieren

APA

Harrison, T. S., Lawrence, D. S., Mwandumba, H. C., Boulware, D. R., Hosseinipour, M. C., Lortholary, O., Meintjes, G., Mosepele, M., & Jarvis, J. N. (2023). How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus–Associated Cryptococcal Meningitis to High-Income Settings?. Clinical Infectious Diseases, 76(5), 944-949. https://doi.org/10.1093/cid/ciac792

Vancouver

Harrison TS, Lawrence DS, Mwandumba HC, Boulware DR, Hosseinipour MC, Lortholary O, et al. How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus–Associated Cryptococcal Meningitis to High-Income Settings?. Clinical Infectious Diseases. 2023;76(5):944-949. doi:10.1093/cid/ciac792

BibTeX
@article{Harrison2023,
  author = {Harrison, Thomas S and Lawrence, David S and Mwandumba, Henry C and Boulware, David R and Hosseinipour, Mina C and Lortholary, Olivier and Meintjes, Graeme and Mosepele, Mosepele and Jarvis, Joseph N},
  title = {How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus–Associated Cryptococcal Meningitis to High-Income Settings?},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {76},
  number = {5},
  pages = {944--949},
  doi = {10.1093/cid/ciac792}
}
Kostenlos starten →